

RECP Best Practices Catalogue

*Study and implementation of a
Trigeneration System*

Developed within the framework of MED TEST II



UNITED NATIONS
INDUSTRIAL DEVELOPMENT ORGANIZATION



The SwitchMed Programme is
funded by the European Union

Best Practice - Study and implementation of a Trigeneration System

SECTOR: Chemical and Pharmaceutical

Branch: Manufacture of basic pharmaceutical products

CATEGORY Technology upgrade/Eco-innovation

APPLICABILITY Utilities

COMPANY SIZE 500



The SwitchMed Programme is funded by the European Union

TEST Training kit

Best Practice - Study and implementation of a Trigeneration System

Description of the Problem (Base Scenario):

Considering that the share of energy keeps increasing the cost price and that the plant uses all three forms of energy namely, Electricity, Heat (Steam and Hot Water) and cold (Iced water), it is interesting to study the opportunity for a Trigeneration system.

Description of the Solution

The solution involves setting up a Trigeneration unit (electricity, heat and cold production) by acquiring a gas engine and an absorption machine. There will be gains in the following areas : energy, environment and finance. The annual production of this unit is:

- 4,600 MWh of electricity,
- 5,400 MWh in the form of hot water (Heat),
- 2,500 MWh in the form of iced water (cold).



The SwitchMed Programme is funded by the European Union

Best Practice - Study and implementation of a Trigeneration System

Economic Gains	Savings of € 165,000
Environmental Gains	Reduced energy losses, energy savings increased by 41.5% and reduction of 1,078 tons of CO ₂ (31.7%)
Health and Safety Impact	-



The SwitchMed Programme is funded by the European Union

Best Practice - Study and implementation of a Trigeneration System

Capital Investments & Financial Indicators	€ 755,000 4.5 years
Supplier Information	-
Other Aspects	Possible technical constraints: Heavy investment and need for highly qualified technicians and rigorous follow-up.
Implementation	The Trigeneration unit has been in production since the end of January 2018,



The SwitchMed Programme is funded by the European Union